Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection

Nephrology

Volumn 12, Issue 1, 2007, Pages 11-17

  Chan, Tak Mao ^a,b   Ho, Stephen K N ^a   Tang, Colin S O ^a   Tse, Kai Chung ^a   Lam, Man Fai ^a   Lai, Kar Neng ^a   Yung, Susan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Dialysis; Hepatitis C; Pegylated interferon

Indexed keywords

ERYTHROPOIETIN; PARACETAMOL; PEGINTERFERON ALPHA2A;

ADULT; AGED; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEPATITIS C; HUMAN; KIDNEY FAILURE; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846999883     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00662.x     Document Type: Article

References (29)

1. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin. Dial. 2005; 18: 52-61.
2. Chan TM, Lok ASF, Cheng IKP, Chan RT. Hepatitis C virus (HCV) infection in hemodialysis patients: A longitudinal study comparing HCV RNA and anti-HCV assays. Hepatology 1993; 17: 5-8.
3. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am. J. Transplant. 2005; 5: 1452-61.
4. Chan TM, Lok ASF, Cheng IKP, Chan RT. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 1993; 104: 862-8.
5. Chan TM, Wu PC, Lau JYN, Lok ASF, Lai CL, Cheng IKP. Interferon therapy for hemodialysis patients with chronic hepatitis C virus (HCV) infection: Its effects on the eradication of HCV and the side-effects in patients with end-stage renal failure. Nephrol. Dial. Transplant. 1997; 12: 1414-19.
6. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-30.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
8. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-82.
9. Gish RG. Standards of treatment in chronic hepatitis C. Semin. Liver Dis. 1999; 19: 35-47.
10. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol. Dial. Transplant. 2005; 20: 991-3.
11. Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 2004; 20: 123-7.
12. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon á-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol. Dial. Transplant. 2006; 21: 437-43.
13. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V. Single-dose pharmacokinetics and safety of pegylated interferon α2b in patients with chronic renal dysfunction. J. Clin. Pharmacol. 2002; 42: 1109-15.
14. Heathcote J, Main J. Treatment of hepatitis C. J. Viral Hep. 2005; 12: 223-35.
15. Puig M, Mihalik K, Yu MY, Feinstone SM, Major ME. Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay. J. Virol. Methods 2002; 105: 253-63.
16. Strader DB, Wright T, Thomas DL, Seelf LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
17. Tan AC, Brouwer JT, Glue P et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study. Nephrol. Dial. Transplant. 2001; 16: 193-5.
18. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J. Viral Hep. 2001; 8: 287-92.
19. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant. Proc. 2004; 36: 1831-4.
20. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis for the treatment of chronic hepatitis C in dialysis patients. Aliment. Pharmacol. Ther. 2003; 18: 1071-81.
21. Degos F, Pol S, Chaix ML et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol. Dial. Transplant. 2001; 16: 1017-23.
22. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000; 343: 1666-72.
23. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000; 343: 1673-80.
24. Barril G, Quiroga JA, Sanz P, Rodriguez-Salvanes F, Selgas R, Carreno V. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: Impact of permeability and pore size of dialysers. Aliment. Pharmacol. Ther. 2004; 20: 37-44.
25. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin. Nephrol. 2005; 63: 232-5.
26. Kokoglu OF, Ucmak H, Hosoglu S et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J. Gastroen. Hepatol. 2006; 21: 575-80.
27. Dhalluin C, Ross A, Leuthold LA et al. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug. Chem. 2005; 16: 504-17.
28. Rustgi VK, Esposito S, Freilich B, Lopez-Talavera J, Lentz E, Shiffman ML. Interim analysis of the safety and efficacy of peginterferon alfa-2a plus ribavirin in chronic hepatitis C patients unable to tolerate or nonresponsive to treatment with peginterferon alfa-2b plus ribavirin. Meeting of the American Association for the Study of Liver Diseases, 11-15 November, 2005, San Francisco, USA Abstract no. 67504.
29. von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.